MedTrace Logo

A Study of VCT220 in Participants With Hypertension and Obesity or Overweight

NCT07360275 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-01-22

No results posted yet for this study

Summary

The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.

Conditions

Interventions

DRUG

VCT220 Tablet

Administered orally, with or without food.

DRUG

VCT220 Placebo Tablet

Administered orally, with or without food.

Sponsors & Collaborators

  • Vincentage Pharma Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2026-10-20
Completion
2026-12-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07360275 on ClinicalTrials.gov